Myocardial Infarction
Systemic inflammation an ‘important risk factor’ for stroke, ILD in rheumatoid arthritis
SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.
FDA approves novel PET radiotracer for evaluation of suspected MI, ischemia
The FDA approved 18F flurpiridaz, a new cardiac PET perfusion radiotracer, for adult patients with known or suspected coronary artery disease being evaluated for myocardial ischemia and infarction.
Neighborhood socioeconomic status linked with heart failure, death for patients with CKD
Neighborhood socioeconomic status was linked with incident heart failure among patients with chronic kidney disease who had more preserved kidney function, study results showed.
Point-of-care testing may expedite movement of patients with ACS from ED to cardiac ward
A bedside cardiac troponin test could reduce the time patients with ACS spend in the ED by nearly 45 minutes, with the availability of a doctor to assess the situation and move them to the cardiac ward, a speaker reported.
AI decision support tool did not improve outcomes among patients with suspected MI
An AI decision support tool embedded in routine care did not meaningfully improve outcomes for patients presenting to the ED with myocardial injury, but showed signs of benefit in an all-comer cohort, a speaker reported.
Wegovy linked to fewer COVID-19-related deaths vs. placebo in SELECT population
In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.
ABYSS trial does not demonstrate safety of beta-blocker interruption after heart attack
In the ABYSS trial, a strategy of interrupting long-term beta-blocker treatment was not noninferior to continued use for the primary composite outcome of death, myocardial infarction, stroke or hospitalization for CV reasons.
New eligibility for semaglutide would cost Medicare billions in spending
High BMI eligibility for semaglutide could cost Medicare up to $145 billion annually, a brief report published in the Annals of Internal Medicine revealed.
Levothyroxine therapy may reduce CV risk for adults with subclinical hypothyroidism
Adults with subclinical hypothyroidism may have a lower risk for major adverse cardiovascular events if they receive levothyroxine therapy compared with no treatment, according to a study published in Thyroid.
SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c
ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.